Back to Journals » Neuropsychiatric Disease and Treatment » Volume 16

CXCL13 Is a Biomarker of Anti-Leucine-Rich Glioma-Inactivated Protein 1 Encephalitis Patients [Letter]

Authors Wei M, Duan Z

Received 30 October 2019

Accepted for publication 13 January 2020

Published 20 January 2020 Volume 2020:16 Pages 181—182

DOI https://doi.org/10.2147/NDT.S236629

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Jun Chen


Mingyu Wei, 1 Zuowei Duan 2

1Medical College of Yangzhou University, Yangzhou 225000, Jiangsu, People’s Republic of China; 2Department of Neurology, The Affiliated Hospital of Yangzhou University, Yangzhou 225000, Jiangsu, People’s Republic of China

Correspondence: Zuowei Duan
Email jydzw061344@163.com

We recently read the original report by Lin and colleagues with great interest. In this study, the authors concluded that both serum and cerebrospinal fluid (CSF) levels of CXCL13, a B cell chemotactic factor, were significantly higher in patients with anti-leucine-rich glioma-inactivated protein 1 (anti-LGI1) encephalitis compared to non-inflammatory neurologic disorder control groups. 1 However, we have some concerns about the interpretation of their data.


A Response to Letter has been published for this article.
View the original paper by Lin and colleagues.





Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]